Summer Sale - Claim 70% Off TipRanks
- Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
- Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks
Sangamo Therapeutics ( (SGMO) ) has provided an update.
On June 23, 2026, Sangamo Therapeutics, Inc. filed for voluntary protection under Chapter 11 in the U.S. Bankruptcy Court in Delaware and will operate as a debtor-in-possession while seeking court approval for debtor-in-possession financing of up to $30 million to support ongoing operations and case administration. The company simultaneously pursued value-maximizing asset sales, entering June 22, 2026 stalking horse agreements to sell core technology platforms and related IP to Eli Lilly for $50 million plus assumed liabilities and to sell its Fabry disease program assets to Astellas for up to $50 million, while implementing a restructuring that cuts about 40% of its U.S. workforce, or 51 roles, leaving roughly 77 employees to advance the assets targeted for sale.
The Chapter 11 process and proposed sales to Lilly and Astellas position Sangamo to monetize its principal R&D platforms and pipeline while reducing costs, but also signal a major strategic retrenchment that could reshape ownership of its technologies and impact employees, partners and creditors as the company seeks to maximize recoveries through court-supervised auctions.
The most recent analyst rating on (SGMO) stock is a Buy
with a $5.00 price target.
To see the full list of analyst forecasts on Sangamo Therapeutics stock,
see the SGMO Stock Forecast page.
Spark’s Take on SGMO Stock
According to Spark, TipRanks’ AI Analyst, SGMO is a Neutral.
The score is held down primarily by weak financial performance (declining revenue, large losses, heavy cash burn, and negative equity implying high financing/dilution risk) and bearish technicals (price below key moving averages with negative MACD). These are partially offset by constructive earnings-call developments on ST-920’s regulatory path and durability data, though timing and execution remain funding-dependent amid listing-related headwinds.
To see Spark’s full report on SGMO stock,
click here.
More about Sangamo Therapeutics
Sangamo Therapeutics, Inc. is a biotechnology company focused on developing genomic medicines, including AAV capsid engineering, zinc finger protein and genome editing platforms, as well as gene therapy programs such as its Fabry disease candidate isaralgagene civaparvovec and a prion disease program, targeting rare and serious conditions.
Average Trading Volume: 9,386,563
Technical Sentiment Signal: Strong Sell
Current Market Cap: $72.19M
For detailed information about SGMO stock, go to TipRanks’ Stock Analysis page.